Drug Shortage Report for MIDAZOLAM INJECTION

Last updated on 2020-09-19 History
Report ID 121647
Drug Identification Number 02242905
Brand name MIDAZOLAM INJECTION
Common or Proper name Midazolam Injection
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) MIDAZOLAM
Strength(s) 5MG
Dosage form(s) LIQUID
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 5 mg/mL, MD Vial, 2 mL
ATC code N05CD
ATC description HYPNOTICS AND SEDATIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2020-08-04
Actual start date
Estimated end date 2020-09-15
Actual end date 2020-09-18
Shortage status Resolved
Updated date 2020-09-19
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to a manufacturing delay, we will be encountering a supply interruption with our C410202 Midazolam Injection 5 mg/mL, MD Vial, 2 mL. Our C410210 Midazolam Injection 5 mg/mL, MD Vial, 10 mL format is available for substitution. Allocations for this code have been increased to cover the 2 mL demand. UPDATE SEP 18 2020 Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Midazolam Injection, 5 mg/mL, MD Vial, 2 mL will be available at all distribution centres by Friday, September 18, 2020. Please note this product will remain on allocation. Contract customers will be allocated 100% of their historical average monthly volumes.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v7 2020-09-19 English Compare
v6 2020-09-18 French Compare
v5 2020-09-18 English Compare
v4 2020-08-05 English Compare
v3 2020-08-04 French Compare
v2 2020-08-04 English Compare
v1 2020-08-04 English Compare

Showing 1 to 7 of 7